Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment
Advanced Science · 2024-12 · 11 (47)
DOI: 10.1002/advs.202403423 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 07.11.2024. Verfasst von Xiaoye Shi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510282, China. Hauptthemen laut MEDLINE: B-Lymphocytes, Immune Checkpoint Inhibitors, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Key Clinical Specialty, Shanghai Key Laboratory of Urologic Diseases.
Abstract (Originalsprache)
B cells are crucial component of humoral immunity, and their role in the tumor immune microenvironment (TME) has garnered significant attention in recent years. These cells hold great potential and application prospects in the field of tumor immunotherapy. Research has demonstrated that the TME can remodel various B cell functions, including proliferation, differentiation, antigen presentation, and antibody production, thereby invalidating the anti‐tumor effects of B cells. Concurrently, numerous immune checkpoints (ICs) on the surface of B cells are upregulated. Aberrant B‐cell IC signals not only impair the function of B cells themselves, but also modulate the tumor‐killing effects of other immune cells, ultimately fostering an immunosuppressive TME and facilitating tumor immune escape. Blocking ICs on B cells is beneficial for reversing the immunosuppressive TME and restoring anti‐tumor immune responses. In this paper, the intricate connection between B‐cell ICs and the TME is delved into, emphasizing the critical role of targeting B‐cell ICs in anti‐tumor immunity, which may provide valuable insights for the future development of tumor immunotherapy based on B cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510282, China.
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, China.
- College of Bioinformatics Science and Technology, Harbin Medical University, 157 Baojian Road. Nangang District, Harbin, Heilongiiang, 150076, China.
- Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, 200433, China.
- Molecular and Experimental Surgery, University Clinic for General-, Visceral-, Vascular- and Trans-Plantation Surgery, Medical Faculty University Hospital Magdeburg, Otto-von Guericke University, 39120, Magdeburg, Germa…
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
ORCID-Profile: Peng Luo
Förderung
- National Natural Science Foundation of China
- Shanghai Municipal Key Clinical Specialty
- Shanghai Key Laboratory of Urologic Diseases
Zitieren
APA
Shi, X., Cheng, X., Jiang, A., Shi, W., Zhu, L., Mou, W., Glaviano, A., Liu, Z., Cheng, Q., Lin, A., Wang, L., & Luo, P. (2024). Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment. Advanced Science, 11(47). https://doi.org/10.1002/advs.202403423
Vancouver
Shi X, Cheng X, Jiang A, Shi W, Zhu L, Mou W, et al. Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment. Advanced Science. 2024;11(47). doi:10.1002/advs.202403423
BibTeX
@article{Shi2024,
author = {Shi, Xiaoye and Cheng, Xiangshu and Jiang, Aimin and Shi, Wenjie and Zhu, Lingxuan and Mou, Weiming and Glaviano, Antonino and Liu, Zaoqu and Cheng, Quan and Lin, Anqi and Wang, Linhui and Luo, Peng},
title = {Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {47},
doi = {10.1002/advs.202403423}
}
EUVIMED